Abstract 3336
Background
The Thoracic Oncology Centre of the University Hospital Zürich, founded in 2011, is certified by the German Cancer Society, and is one of 17 multidisciplinary organ-based centres of the CCCZ. All treatment recommendations are made at a multidisciplinary tumor board. Since 1980, all new cancer cases among the population of both cantons Zurich and Zug, are registered in the KKR.
Methods
The aim of the current study is to quantify the mortality risk of patients with NSCLC and identify differences on survival time and other factors between patients receiving their primary treatment at the CCCZ and those treated elsewhere and registered by KKR. Association of sex, histology, stage and age at initial diagnosis to survival as well as differential effect on survival between CCCZ and KKR are also explored. Imputation of last follow-up date of KKR by the database cut-off date (7 August 2018) was used, to address possible underestimation of survival due to missingness in this centre.
Results
Patients included 848 primary cases from the CCCZ and 1761 cases from the KKR diagnosed between January 1, 2011 and December 31, 2015. A comparable median follow-up time of 57 months and 56 months for CCCZ and KKR patients, respectively, was calculated. OS is significantly superior for CCCZ patients as compared to KKR patients (median: 36.0m, 95%CI:[31.0, 45.0] versus 12.0m, 95%CI:[11.0, 13.0];HR=1.71 [95% CI 1.54, 1.90] p < 0.001). This difference remained significant when examined in the subgroups of gender, age (≤65 and >65y), UICC stage (I/II, III, IV), and histology (squamous, adenocarcinoma). The effect of treatment outside or within the CCCZ on patients’ survival remained significant (HR = 1.42 [95% CI 1.27, 1.57]; p < 0.001) in multivariate analysis adjusting for sex, histology, UICC stage and age at diagnosis, all factors with a significant effect on OS.
Conclusions
Our analysis provides further evidence of the importance of the volume of experience and the availability of a multidisciplinary organisation and research environment, as delivered by a comprehensive cancer centre, on the outcome of patients with all stages of NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Comprehensive Cancer Center Zürich.
Funding
Has not received any funding.
Disclosure
R.A. Stahel: Advisory / Consultancy: I have received honoraria as a consultant at advisory boards from AbbVie, AstraZeneca, Boehringer Ingelheim, MSD, Pfizer, Roche and Takeda.; Speaker Bureau / Expert testimony: I have received honoraria as a speaker from AstraZeneca, Boehringer Ingelheim, MSD and Roche.; Honoraria (self): Roche and Takeda; Research grant / Funding (institution), ETOP trials (president and scientific chair): AstraZeneca, BMS, Boehringer Ingelheim, Genentech, MSD, Roche, and Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
592 - Effects of novel targeted anticancer drugs on cytotoxicity, apoptosis, angiogenesis, EMT, drug resistance and autophagic mechanism
Presenter: Seyma Aydinlik
Session: Poster Display session 1
Resources:
Abstract
3235 - Delineating the mechanisms of alpha 1-3 fucosyltransferase FUT11 in ovarian cancer
Presenter: Qi Chen
Session: Poster Display session 1
Resources:
Abstract
3577 - The tyrosine kinase inhibitor Dasatinib blocks tumor growth, invasion and recurrence potential by interrupting the communication between cancer cells and their surrounding microenvironment in triple negative breast cancer
Presenter: Miriam Nuncia-Cantarero
Session: Poster Display session 1
Resources:
Abstract
4808 - NORE1A induces a feedback termination of TNF signaling by antagonizing TNFR1 through ITCH-mediated destruction complex
Presenter: Jieun Ahn
Session: Poster Display session 1
Resources:
Abstract
1294 - Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small-cell cell lung cancer cell models
Presenter: Jordi Codony-Servat
Session: Poster Display session 1
Resources:
Abstract
1559 - Expression of IL-17RA promotes cancer stem-like properties of colorectal cancer cells by Stat3 activation
Presenter: Chih-Yung Yang
Session: Poster Display session 1
Resources:
Abstract
1615 - Adaption of Pancreatic Cancer Cells to AKT1 Inhibition Induces the Acquisition of Cancer Stem-Cell Like Phenotype Through Upregulation of Mitochondrial Functions
Presenter: Hugo Arasanz
Session: Poster Display session 1
Resources:
Abstract
4793 - Bub3 is phosphorylated by the Ataxia-Telangiectasia Mutated Kinase in mitosis and required for activation of the mitotic spindle checkpoint in Breast Cancer
Presenter: Mingming Xiao
Session: Poster Display session 1
Resources:
Abstract
1448 - The regulation of INK4 locus by long non-coding RNAs
Presenter: Yojiro Kotake
Session: Poster Display session 1
Resources:
Abstract
1858 - Vascular Endothelial Growth Factor in Colorectal Cancer Pathology, Survival and Treatment
Presenter: Liz Baker
Session: Poster Display session 1
Resources:
Abstract